Possible andrologic markers in elevated neonatal 17-hydroxyprogesterone

Area of Science:

• Pediatric Endocrinology
• Reproductive Endocrinology
• Neonatal Health

Background:

• Neonatal screening often identifies infants with elevated 17-hydroxyprogesterone (17OH-P).
• The implications of elevated neonatal 17OH-P on early endocrine development, particularly the hypothalamic-pituitary-testis (HPT) axis, require further investigation.

Purpose of the Study:

• To investigate the status of the hypothalamic-pituitary-testis axis in male infants with elevated neonatal 17-hydroxyprogesterone (17OH-P) within the first six months of life.

Main Methods:

• Prospective analysis of 30 male infants with increased neonatal 17OH-P (patients).
• Comparison with 52 age-matched healthy control subjects.
• Measurement of serum testosterone (T), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and inhibin B levels.

Main Results:

• No significant differences were observed in testosterone (T), FSH, or LH levels between patients and control subjects.
• Inhibin B levels were significantly higher in male infants with elevated neonatal 17OH-P compared to controls.

Conclusions:

• Elevated neonatal 17-hydroxyprogesterone (17OH-P) may be associated with altered early reproductive hormone profiles, specifically higher inhibin B.
• Clinical follow-up of these infants through childhood and puberty is warranted to assess the long-term evolution of their endocrine status and HPT axis function.